Treatment outcome of pulmonary tuberculosis in eastern Taiwan - Experience at a Medical Center

Journal of the Formosan Medical Association

Volumn 106, Issue 1, 2007, Pages 25-30

  Lee, Jen Jyh ^a   Wu, Rong Lun ^a   Lee, Yeong Sheng ^b   Wu, Yi Chun ^b   Chiang, Chen Yuan ^c,d  

^a TZU CHI UNIVERSITY   (Taiwan)

^b CENTER FOR DISEASE CONTROL   (Taiwan)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d NONE   (Taiwan)

Author keywords

Pulmonary tuberculosis; Taiwan; Treatment outcome

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER; CHILD; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG FEVER; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER CIRRHOSIS; LUNG CAVITATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PNEUMOCONIOSIS; SPUTUM EXAMINATION; SURVIVAL RATE; TAIWAN; THORAX RADIOGRAPHY; TOXIC HEPATITIS; TREATMENT OUTCOME; UREMIA;

EID: 33846876596     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60212-6     Document Type: Article

References (16)

1. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis. Global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-21.
2. Dye C, Scheele S, Dolin P, et al. Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country. JAMA 1999;282:677-86.
3. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. Geneva: World Health Organization, 2004. WHO/HTM/TB/2004.331.
4. Veen J, Raviglione M, Rieder HL, et al. Standardized tuberculosis treatment outcome monitoring in Europe. Eur Respir J 1998;12:505-10.
5. World Health Organization. Forty-fourth World Health Assembly, Resolutions and Decisions. Geneva: World Health Organization, 1991. WHA44/1991/REC/1.
6. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2005. Geneva: World Health Organization, 2005. WHO/HTM/TB/2005.49.
7. Center for Disease Control, Department of Health. Statistics of Communicable Diseases and Surveillance Report in Taiwan Area 2003. Taipei: Department of Health, The Executive Yuan, Taipei, Taiwan, 2004.
8. Information obtained from http://203.65.72.83/ch/dt/upload/QC/ QC_index.htm (Taiwan CDC website) on July 1, 2004.
9. Center for Disease Control. Tuberculosis Annual Report 2001. Taipei: Center for Disease Control, Department of Health, Taipei, Taiwan, 2002.
10. Chiang CY, Hsu CJ, Huang RM, et al. Antituberculosis drug resistance among retreatment tuberculosis patients in a referral center in Taipei. J Formos Med Assoc 2004;103:411-5.
11. Luelmo F, Frieden T. What are the indicators of an effective tuberculosis control programme? In: Toman's Tuberculosis. Geneva: World Health Organization, 2004.
12. Enarson DA, Rieder HL, Arnadottir T, et al. Management of Tuberculosis. A guide for Low Income Countries, 5th edition. Paris: International Union Against Tuberculosis and Lung Disease, 2000.
13. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes, 3rd edition. Geneva: World Health Organization, 2003. WHO/CDS/TB/2003; 313:1-108.
14. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis. Consensus statement of the public health tuberculosis guidelines panel. JAMA 1998;279:943-8.
15. Jasmer RM, Seaman CB, Gonzalez LC, et al. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med 2004;170:561-6.
16. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-84.